The BioBusiness and MedTech Business programs will be combined into a new entrepreneurship program: “Bio- and MedTech Business” with two different, sector-specific, BioTech and MedTech branches and an Investor Forum. The admission procedure is based on interviews.
This book (eds. Heidrun Flaadt & Joerg Dogwiler) helps emerging start-ups in the field of eHealth understand and develop the keys to success. We thank USI for supporting the publication in the frame of the “Innovation in Teaching” project.
We warmly thank Joerg Dogwiler, CASE BioMed Advisory Board member and Founder of Congenius for his very valuable continuous support. Congenius provides tailored expertise to aspiring start-ups in the medical device, in vitro diagnostics and pharmaceutical industry.
Founded by Dr. Marc Gitzinger, BioBusiness2010 alumnus, BioVersys is fighting against bacterial infections by focusing on development of small molecules that work by novel modes of action and against novel targets. BioVersys, an ETHZ spin-off, is an award winning company.
Emuno, co-founded by BioBusiness2023 alumna Dr. Emilia Neuwirt, received an EIC Transition Grant (2,5 million euros) from the European Innovation Council (EIC). Emuno develops therapeutics to treat autoimmune disorders and to overcome cancer immune evasion.
What an incredible experience at BioBusiness2024 in Lugano! I am very grateful for the opportunity to engage with such brilliant entrepreneurs in an inspiring environment with discussions that are critical for business success.
